RxDoctor Payments Data

Sarah Thomas

Acute Care · Jonesboro, ARNPI 1598193468

Payments from drug & device makers

$1,166in general payments, 2019–2025

Across 43 payments — averaging $27.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$293
  • Novartis$263
  • Edwards Lifesciences$129
  • Novo Nordisk$95
  • Cvrx, Inc.$61
  • Amgen$50
  • plus $275 from 11 others

What the payments were for

  • Food & beverage$1,166100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,166 in reported general payments places this provider in the 65th percentile of 321 acute care providers in Arkansas.

See all acute care providers in Arkansas

Medicare billing

Part B allowed, 2024
$20,936
Medicare patients
214
Services billed
435

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$64,919
Repatha SureclickEvolocumab39$48,045
EliquisApixaban18$9,356
NexletolBempedoic Acid12$6,109
Ezetimibe84$1,124
Colchicine29$631
Rosuvastatin Calcium52$425
Atorvastatin Calcium66$393
Amlodipine Besylate41$252
Fenofibrate20$197
Losartan Potassium12$149
Nitroglycerin15$114
Levothyroxine Sodium12$108
Carvedilol20$97
Furosemide30$80

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$95$64,91966 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 321 acute care providers in Arkansas.

Other acute care in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →